US FDA’s Gene Therapy Work Feeling The Effects Of Pandemic Response
Executive Summary
CBER’s heavy COVID-19 workload is pushing other things to the side, causing delays in sponsor meetings and issuance of new guidance documents, and a slowdown in efforts to streamline development of individualized therapeutics, biologics center leaders tell BIO Digital 2020.
You may also be interested in...
Gene Editing: Off-Target Effects Should Be A Key Safety Focus During Development, US FDA Says
Clinical development programs for human gene therapy products that incorporate genome editing should address the potential risks of off-target editing as well as unintended consequences of on-target effects, agency says in new draft guidance.
COVID-19’s Damage To Gene Therapy Development May Last Years
US FDA's Peter Marks says the field is robust, but hedges on approval predictions for the coming years because of pandemic’s effect.
Is The US FDA At A Tipping Point?
Wall Street is worried that a cluster of recent negative regulatory events means tougher reviews going forward. That concern is probably overdone, but a year into the COVID pandemic is a good time to take stock of how FDA is doing.